SBL
ESPR

Sargent Bickham Lagudis’s Esperion Therapeutics ESPR Stock Holding History

Sargent Bickham Lagudis’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-88
Closed -$1K – 721
2016
Q3 		$1K Hold
88
– – ﹤0.01% 694
2016
Q2 		$1K Hold
88
– – ﹤0.01% 682
2016
Q1 		$1K Buy
+88
New +$1.42K ﹤0.01% 699

Other funds holding ESPR

PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Sargent Bickham Lagudis's ESPR Position: Q4 2016 in Review

Sargent Bickham Lagudis sold out of Esperion Therapeutics (ESPR) in Q4 2016, closing a stake of 88 shares — an estimated $1K sold.

Sargent Bickham Lagudis first reported a position in ESPR in Q1 2016 and held it in 3 quarters. The position peaked at $1K in Q3 2016. 99 funds tracked by Wall St. Rank hold ESPR as of Q4 2016.

  • Sargent Bickham Lagudis reported no remaining Esperion Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Sargent Bickham Lagudis sold 88 Esperion Therapeutics shares in Q4 2016, an estimated $1K.
  • Sargent Bickham Lagudis first reported a position in Esperion Therapeutics in Q1 2016 and held it in 3 quarters.
  • Sargent Bickham Lagudis's Esperion Therapeutics position peaked at $1K in Q3 2016.
  • 99 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2016.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2016, filed 13 Sep 2021.